About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a company based in Dublin (Ireland) founded in 2003 by Bruce C Cozadd. Jazz Pharmaceuticals has raised $265 million across 3 funding rounds from investors including KKR, Thoma Bravo and Longitude Capital. The company has 2,800 employees as of December 31, 2024. Jazz Pharmaceuticals has completed 5 acquisitions, including Cavion, Chimerix and EUSA Pharma. Jazz Pharmaceuticals offers products and services including Epidiolex, Xywav, and Defitelio. Jazz Pharmaceuticals operates in a competitive market with competitors including C4 Therapeutics, Erasca, MiRagen, Mereo BioPharma and Nimbus Therapeutics, among others.
- Headquarter Dublin, Ireland
- Employees 2800 as on 31 Dec, 2024
- Founders Bruce C Cozadd
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Jazz Pharmaceuticals Plc
-
Annual Revenue
$4.07 B (USD)6.12as on Dec 31, 2024
-
Net Profit
$560.12 M (USD)35.02as on Dec 31, 2024
-
EBITDA
$1.39 B (USD)6.84as on Dec 31, 2024
-
Total Equity Funding
$265 M (USD)
in 3 rounds
-
Latest Funding Round
$7 M (USD), Post-IPO
Jul 07, 2009
-
Investors
KKR
& 11 more
-
Employee Count
2800
as on Dec 31, 2024
-
Investments & Acquisitions
Cavion
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Jazz Pharmaceuticals
Jazz Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol JAZZ in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Jazz Pharmaceuticals
Jazz Pharmaceuticals offers a comprehensive portfolio of products and services, including Epidiolex, Xywav, and Defitelio.
Cannabidiol-based treatment for epilepsy and seizures.
Oral solution for narcolepsy and related disorders.
Treatment for severe hepatic veno-occlusive disease.
People of Jazz Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
223 people
Software Development Team
103 people
Sales and Marketing
70 people
Senior Team
66 people
Product Management Team
56 people
Finance and Accounting
37 people
Data Analysis and Operations Team
31 people
Human Resources and Administration
30 people
Unlock access to complete
Funding Insights of Jazz Pharmaceuticals
Jazz Pharmaceuticals has successfully raised a total of $265M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7 million completed in July 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Jazz Pharmaceuticals
Jazz Pharmaceuticals has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include KKR, Thoma Bravo and Longitude Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
Private markets investment management with strategies in equity, credit, and secondary investments.
|
Locked | Locked | Locked | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked |
Investor details for Jazz Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Jazz Pharmaceuticals
Jazz Pharmaceuticals has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Cavion, Chimerix and EUSA Pharma.
Investment portfolio details for Jazz Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer and commercializer of pharmaceutical medicines
|
Locked | Locked | 2006 | Locked | |
|
Targeted therapies for neuropathic pain and brain cancer are developed.
|
Locked | Locked | 2005 | Locked | |
|
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
Locked | Locked | 2002 | Locked |
Complete acquisition details for Jazz Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Jazz Pharmaceuticals
Detailed financials for Jazz Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Jazz Pharmaceuticals Comparisons
Peer comparison for Jazz Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Jazz Pharmaceuticals
Jazz Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as C4 Therapeutics, Erasca, MiRagen, Mereo BioPharma and Nimbus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Jazz Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Jazz Pharmaceuticals
Complete news archive for Jazz Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jazz Pharmaceuticals
Jazz Pharmaceuticals was founded in 2003.
Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
Bruce C Cozadd is the current CEO of Jazz Pharmaceuticals. They have also founded this company.
Jazz Pharmaceuticals is a funded company, having raised a total of $265M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Jazz Pharmaceuticals is 2,800.
Annual revenue of Jazz Pharmaceuticals is $4.07B as on Dec 31, 2024.
Jazz Pharmaceuticals was founded in 2003 and is headquartered in Dublin, Ireland. Biopharmaceutical products are developed and commercialized by the company to address unmet medical needs across various therapeutic areas. Clinical trial programs are conducted to support these medicines, alongside patient support resources. Research is prioritized based on patient requirements, with advancements made in treating specific conditions. Corporate giving and sustainability initiatives are also pursued.
Jazz Pharmaceuticals's top competitors include C4 Therapeutics, Erasca and Nimbus Therapeutics.
Jazz Pharmaceuticals offers Epidiolex, Xywav, and Defitelio.
Yes, Jazz Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol JAZZ.
Jazz Pharmaceuticals has made 5 acquisitions, including Cavion, Chimerix, and EUSA Pharma.
Jazz Pharmaceuticals has 12 investors. Key investors include KKR, Thoma Bravo, Longitude Capital, Adams Street Partners, and Versant Ventures.
The ticker symbol of Jazz Pharmaceuticals is JAZZ on NASDAQ.